Amylyx Pharmaceuticals (AMLX) Institutional Ownership

During the previous two years, 145 institutional investors and hedge funds held shares of Amylyx Pharmaceuticals. The most heavily invested institutionals were Stonepine Capital Management LLC ($36.80M), Rock Springs Capital Management LP ($33.32M), Perceptive Advisors LLC ($27.51M), Great Point Partners LLC ($20.90M), Adage Capital Partners GP L.L.C. ($20.17M), Franklin Resources Inc. ($19.50M), and Emerald Advisers LLC ($15.35M).Learn more on AMLX's institutional investors.

95.84% of Amylyx Pharmaceuticals stock is owned by institutional investors. Learn more on AMLX's institutional investor holdings.

Of the 124 institutional investors that purchased Amylyx Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Adage Capital Partners GP L.L.C. ($6.63M), AQR Capital Management LLC ($3.22M), Millennium Management LLC ($2.63M), abrdn plc ($2.05M), Almitas Capital LLC ($2.04M), Boxer Capital Management LLC ($1.75M), and Woodline Partners LP ($1.61M).

Institutional investors have bought a total of 43,379,601 shares in the last 24 months. This purchase volume represents approximately $274.72M in transactions.

Of the 55 institutional investors that sold Amylyx Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Perceptive Advisors LLC ($1.98M), Avidity Partners Management LP ($1.69M), Federated Hermes Inc. ($1.43M), Alyeska Investment Group L.P. ($1.27M), Millennium Management LLC ($976.28K), Jane Street Group LLC ($581.22K), and Allspring Global Investments Holdings LLC ($524.60K).

Institutional investors have sold a total of 13,687,042 shares in the last 24 months. This volume of shares sold represents approximately $139.98M in transactions.